Rallybio Corp.

Najat Khan has built her career at the intersection of drug development and technological innovation. As chief R&D and commercial officer at Recursion, she is helping to scale one of biotech’s (or

Biotech valuations and funding availability went into reverse in the second half of 2021, following a period of abundant financing. Meanwhile, big pharma companies face their own problems, with many b

About two months after announcing that it was reducing its workforce by 45% and focusing on two core R&D programs, Rallybio Corp. has gotten support from pharma giant Johnson & Johnson for its eff

The pace of new financings seems to be picking up in 2024 after a decline in the fourth quarter of 2023 relative to the last quarter of 2022, but some drug developers still are struggling to raise new